



Datroway
Datroway (Datopotamab Deruxtecan-dlnk)
J9011

Prior Authorization Request Medicare Part B Form

*Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.*

<input type="checkbox"/>	Standard Request– (72 Hours)	<input type="checkbox"/>	Urgent Request (standard time frame could place the member's life, health or ability in serious jeopardy)
Date Requested _____			
Requestor _____ Clinic name: _____ Phone _____ / Fax _____			

MEMBER INFORMATION

*Name: _____ *ID#: _____ *DOB: _____

PRESCRIBER INFORMATION

*Name: _____ MD FNP DO NP PA *Phone: _____

*Address: _____ *Fax: _____

DISPENSING PROVIDER / ADMINISTRATION INFORMATION

*Name: _____ Phone: _____

*Address: _____ Fax: _____

PROCEDURE / PRODUCT INFORMATION

HCPC Code	Name of Drug	Dose (Wt: _____ kg Ht: _____)	Frequency	End Date if known

Self-administered Provider-administered Home Infusion

Chart notes attached. **Other important information:** _____

Diagnosis: ICD10: _____ **Description:** _____

Provider attests the diagnosis provided is an FDA-Approved indication for this drug

CLINICAL INFORMATION

New Start or Initial Request: (Clinical documentation required for all requests)

Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer

- Patient has unresectable or metastatic breast cancer AND
- Tumor is hormone receptor (HR)-positive AND
- Tumor is HER2-negative (IHC 0, 1+, or IHC 2+/ISH-) AND
- Patient received prior endocrine-based therapy & at least one systemic therapy for metastatic disease AND
- ECOG performance status 0-1 AND
- No history of interstitial lung disease requiring steroids or current ILD

Unresectable or Metastatic Non-Small Cell Lung Cancer

- Patient has unresectable or metastatic NSCLC AND
- Patient has received prior systemic therapy (including targeted therapy if actionable mutation present) AND
- ECOG performance status 0-1 AND
- No history of interstitial lung disease requiring steroids or current ILD

If not, please provide **clinical rationale** for formulary exception: _____

Continuation Requests: (Clinical documentation required for all requests)

Patient had an **adequate response** or **significant improvement** while on this medication.

Medical record documentation of positive response is included

If not, please provide clinical rationale for continuing this medication: _____

ACKNOWLEDGEMENT

Request By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties. **THIS AUTHORIZATION IS NOT A GUARANTEE OF PAYMENT.** PAYMENT IS BASED ON BENEFITS IN EFFECT AT THE TIME OF SERVICE, MEMBER ELIGIBILITY AND MEDICAL NECESSITY.

Prior Authorization Group – Datroway Prior Authorization

Drug Name(s):

DATROWAY

DATOPOTAMAB DERUXTECAN-DLNK

Criteria for approval of Non-Formulary/Preferred Drug:

1. Prescribed for an approved FDA diagnosis (as listed below):
2. Prescribed by, or in consultation with an oncologist or other cancer specialist related to the diagnosis.
3. Drug is being used appropriately per NCCN, CMS recognized compendia, authoritative medical literature, evidence based guidelines and/or accepted standards of medical practice.
4. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
 - If the member meets all these criteria, they may be approved by the Plan for the requested drug.
 - Quantity limits and tiering will be determined by the Plan, in accordance with the Label.

Exclusion Criteria:

N/A

Prescriber Restrictions:

Oncologist or other related specialist

Coverage Duration:

Approval will be for 6 months

FDA Indications:

Datroway

- Breast cancer, Unresectable or metastatic, hormone-receptor positive, HER2-negative, IHC 0, IHC 1+ or IHC 2+/ISH-, in patients who have received prior endocrine-based therapy and chemotherapy/View additional information.
- Non-small cell lung cancer, Locally advanced or metastatic, EGFR-mutated, previously treated with EGFR-directed therapy and platinum-based chemotherapy

Off-Label Uses:

N/A

Age Restrictions:

Safety and efficacy not established in pediatric patients

Other Clinical Consideration:

N/A

Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/39D5C7/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/1FB830/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=934644&contentSetId=100&title=Datopotamab+Deruxtecandlnk&servicesTitle=Datopotamab+Deruxtecandlnk&brandName=Datroway&UserMdxSearchTerm=Datroway#